| Entry |
|
|---|
| Name |
Pyridostigmine bromide (JP18/USP/INN);
Mestinon (TN) |
|---|
| Product |
|
|---|
| Generic |
PRYIDOSTIGMINE BROMIDE (Athem LLC), PRYIDOSTIGMINE BROMIDE (Rising Pharma Holdings), PYRIDOSTIGMINE (Novitium Pharma LLC), PYRIDOSTIGMINE BROMIDE (ANI Pharmaceuticals), PYRIDOSTIGMINE BROMIDE (Acella Pharmaceuticals), PYRIDOSTIGMINE BROMIDE (Alvogen), PYRIDOSTIGMINE BROMIDE (American Health Packaging), PYRIDOSTIGMINE BROMIDE (Amneal Pharmaceuticals NY LLC), PYRIDOSTIGMINE BROMIDE (Amneal Pharmaceuticals of New York LLC), PYRIDOSTIGMINE BROMIDE (Amneal Pharmaceuticals of New York LLC), PYRIDOSTIGMINE BROMIDE (Major Pharmaceuticals), PYRIDOSTIGMINE BROMIDE (McKesson Corporation dba SKY Packaging), PYRIDOSTIGMINE BROMIDE (Method Pharmaceuticals), PYRIDOSTIGMINE BROMIDE (Novadoz Pharmaceuticals LLC), PYRIDOSTIGMINE BROMIDE (Oceanside Pharmaceuticals), PYRIDOSTIGMINE BROMIDE (Oceanside Pharmaceuticals), PYRIDOSTIGMINE BROMIDE (Oceanside Pharmaceuticals), PYRIDOSTIGMINE BROMIDE (Rising Pharmaceuticals), PYRIDOSTIGMINE BROMIDE (VistaPharm), PYRIDOSTIGMINE BROMIDE (Woodward Pharma Services LLC), PYRIDOSTIGMINE BROMIDE (Zydus Lifesciences Limited), PYRIDOSTIGMINE BROMIDE (Zydus Pharmaceuticals (USA)) |
|---|
| Formula |
C9H13N2O2. Br
|
|---|
| Exact mass |
260.016
|
|---|
| Mol weight |
261.1157
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01595 Cholinesterase inhibitor
DG01593 Acetylcholinesterase inhibitor
DG01719 Parasympathomimetic agent
|
|---|
| Remark |
| Therapeutic category: | 1233 |
| Product (DG00988): | D00487<JP/US> |
|
|---|
| Efficacy |
Acetylcholinesterase inhibitor |
|---|
| Disease |
|
|---|
| Comment |
Physostigmine derivative
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07220 | Cholinergic and anticholinergic drugs |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N07 OTHER NERVOUS SYSTEM DRUGS
N07A PARASYMPATHOMIMETICS
N07AA Anticholinesterases
N07AA02 Pyridostigmine
D00487 Pyridostigmine bromide (JP18/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antimyasthenic Agents
Pyridostigmine
D00487 Pyridostigmine bromide (JP18/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
12 Agents affecting peripheral nervous system
123 Autonomic nervous system agents
1233 Neostigmines
D00487 Pyridostigmine bromide (JP18/USP/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01595 Cholinesterase inhibitor
DG01593 Acetylcholinesterase inhibitor
DG00988 Pyridostigmine
D00487 Pyridostigmine bromide
DG01719 Parasympathomimetic agent
DG00988 Pyridostigmine
D00487 Pyridostigmine bromide
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Carboxylic-ester hydrolases
ACHE
D00487 Pyridostigmine bromide (JP18/USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00487 Pyridostigmine bromide
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01595 Cholinesterase inhibitor
DG01593 Acetylcholinesterase inhibitor
DG00988 Pyridostigmine
DG01719 Parasympathomimetic agent
DG00988 Pyridostigmine
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 14
1 C8y C 22.7500 -20.9300
2 O7a O 21.4900 -20.2300
3 C8x C 22.7500 -22.3300
4 C8x C 23.9400 -20.2300
5 C7a C 20.3000 -20.9300
6 N5y N 23.9400 -23.0300 #+
7 C8x C 25.1300 -20.9300
8 N1c N 19.1100 -20.2300
9 O6a O 20.3000 -22.3300
10 C8x C 25.1300 -22.3300
11 C1a C 23.9400 -24.4300
12 C1a C 17.8500 -20.9300
13 C1a C 19.1100 -18.8300
14 X Br 26.6700 -23.1700 #-
BOND 13
1 1 2 1
2 1 3 1
3 1 4 2
4 2 5 1
5 3 6 2
6 4 7 1
7 5 8 1
8 5 9 2
9 6 10 1
10 6 11 1
11 8 12 1
12 8 13 1
13 7 10 2
|
|---|
